# A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

> **NCT05090371** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 136 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Disease modifying treatment (DMT)

## Key facts

- **NCT ID:** NCT05090371
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2027-04-13
- **Final completion:** 2027-04-13
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05090371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05090371, "A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05090371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*